Comparative in vitro activity of lomefloxacin, a new difluoroquinolone.
The in vitro activity of lomefloxacin, a new difluoroquinolone, was compared with that of norfloxacin, ciprofloxacin, gentamicin and ceftazidime against a total of 577 recent clinical isolates. MICs were determined by a standard agar dilution procedure, and two inocula (10(4) and 10(6) CFU) were used throughout. Lomefloxacin inhibited most species of the Enterobacteriaceae, Staphylococcus aureus (including methicillin-resistant strains) and Haemophilus influenzae at less than or equal to 1 mg/l. Pseudomonas aeruginosa (MIC 90, 4 mg/l) was somewhat more resistant, and Pseudomonas maltophilia (MIC 90, 16 mg/l) and the Bacteroides fragilis group (MIC 90, 32 mg/l) were considerably more resistant. Overall, lomefloxacin was as active as norfloxacin, but was two- to eightfold less active than ciprofloxacin against most species tested.
Clarke
A M
AM
Division of Medical Microbiology, St. Paul's Hospital, Vancouver, British Columbia, Canada.
Zemcov
S J
SJ
D000890:Anti-Infective Agents / Q000008:administration & dosage / Q000493:pharmacokinetics*; D001420:Bacteria, Aerobic / Q000187:drug effects*; D001421:Bacteria, Anaerobic / Q000187:drug effects*; D002442:Ceftazidime / Q000008:administration & dosage / Q000493:pharmacokinetics; D002939:Ciprofloxacin / Q000008:administration & dosage / Q000493:pharmacokinetics; D004353:Drug Evaluation, Preclinical; D024841:Fluoroquinolones; D005839:Gentamicins / Q000008:administration & dosage / Q000493:pharmacokinetics; D008826:Microbial Sensitivity Tests; D009643:Norfloxacin / Q000008:administration & dosage / Q000493:pharmacokinetics; D015363:Quinolones
D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D005839:Gentamicins; D015363:Quinolones; D002939:Ciprofloxacin; D002442:Ceftazidime; C053091:lomefloxacin; D009643:Norfloxacin